Cinnamomum Cassia Effect on IGF1 and Metabolic Control in Patients With DM2 Without Glycemic Control Metformin Treated

NCT03610412 | Completed Phase 3

• 1 other identifier: R-2018-1301-031
• Study Type: interventional
• Target: 28
• Locations: 1 country
• Sites: 1

Brief Summary

Among the multiple treatment options for Diabetes Mellitus Type 2 (DM2), the influence on Insuline like growth factor 1 (IGF1) plays a causal role in diabetes but has shown similarities with insulin, both in its structure and in its function, including a rapid reduction in glucose levels in blood, could improve glycemic control in patients. Oral administration of 3 g of cinnamomum cassia for 90 days acts as an enhancer of the IGF1 insulin response and on metabolic control (fasting glucose, glycosylated hemoglobin (HbA1c), triglycerides, total cholesterol, high density cholesterol, low density cholesterol, very low density cholesterol, systolic and diastolic blood pressure (TAS and TAD), body weight) in patients with DM2 without glycemic control treated with metformin at doses ≤ 850 mg daily.

Conditions

Diabetes Mellitus, Type 2

Keywords

Diabetes Mellitus Type 2; IGF1; Cinnamomum cassia; Metabolic control; Metformin

Outcome Measures

Primary Outcomes (6)

• The effect of cinnamomum cassia on IGF1 levels.

  Changes in the levels of IGF1

  90 days

• The effect of cinnamomum cassia potentiates the insulin response of IGF1 on metabolic control in patients with DM2 without glycemic control treated with metformin.

  Changes in the levels of the fasting glucose decrease and glycated hemoglobin

  90 days

• The effect of cinnamomum cassia on metabolic control in patients with DM2 without glycemic control treated with metformin

  Changes in the levels of total cholesterol

  90 days

• The effect of cinnamomum cassia on metabolic control

  Changes in the levels of tryglicerides

  90 days

• The effect of cinnamomum cassia on blood pressure

  Changes in the levels of systolic and diastolic blood pressure

  90 days

• The effect of cinnamomum cassia on body weight

  Changes in the body weight

  90 days

Secondary Outcomes (4)

• The effect of cinnamomum cassia potentiates the IGF1 insulin response on insulin sensitivity.

  90 days

• The effect of cinnamomum cassia potentiates the IGF1 insulin response on BMI.

  90 days

• The effect of cinnamomum cassia potentiates the IGF1 insulin response on waist circumference.

  90 days

• The effect of cinnamomum cassia potentiates the IGF1 insulin response on body fat%.

  90 days

Study Arms (2)

Cinnamomum Cassia

ACTIVE COMPARATOR

A group of 14 patients (7 women and 7 men) with DM2 without adequate control, treated with metformin 850mg daily, who will receive 1g of cinnamomum cassia orally every 8 hours, for 90 days.

Other: Cinnamomum Cassia

Placebo

PLACEBO COMPARATOR

A group of 14 patients (7 women and 7 men) with DM2 without adequate control, treated with metformin 850mg daily, who will receive 1g of placebo (calcined magnesia) orally every 8 hours, for 90 days.

Other: Placebo (calcined magnesia)

Interventions

Cinnamomum Cassia OTHER

The intervention period will be 90 days, unlike other trials with Cinnamomum cassia and the main effect sought is on IGF1 levels, in addition to metabolic control.

Cinnamomum Cassia

Placebo (calcined magnesia) OTHER

The intervention period will be 90 days, unlike other trials with Cinnamomum cassia and comparison with placebo. The main effect sought is on IGF1 levels, in addition to metabolic control.

Placebo

Eligibility Criteria

• Age: 40 Years - 59 Years
• Gender Eligibility Details: The sample size will be 28 patients, 14 men and 14 women.
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Signature of consent under written information prior to the completion of any procedure in the study.
• Men and women aged 40 to 59 years old, residents of Guadalajara, Jalisco and the metropolitan area.
• Ability to communicate and meet all the requirements of the study.
• BMI less than or equal to 34.9 kg / m2.
• Diagnosis of DM2 according to the ADA:
• Plasmatic glucose ≥126mg / dl (7.0 mmol / L) in an 8-hour fast.
• Plasmatic glucose ≥200mg / dl (11.1 mmol / L) at 2 hours after an oral glucose tolerance test.
• or HbA1C ≥6.5% (48 mmol / mol).
• o Plasmatic glucose ≥200mg / dl (11.1 mmol / L) in a random sample to the patient with classic symptoms of hyperglycemia.
• Evolution of DM2 less than 1 year.
• Be receiving pharmacological treatment with metformin in doses less than or equal to 850mg.
• Stable body weight within 3 months prior to the start of the study, defined as a variability in body weight of less than 10%.
• Eumenorrheic women with mechanical or definitive contraceptive method without hormonal treatment.

You may not qualify if:

• Determination of HbA1c less than 6.5%, greater than 10% or fasting glucose greater than 250 mg / dL.
• Serum total cholesterol concentration greater than or equal to 240mg / dl.
• Serum triglyceride concentration greater than or equal to 400mg / dl.
• History of hypersensitivity to study drugs.
• Intake of drugs with known effects on glucose metabolism, lipids, and weight.
• Uncontrolled arterial hypertension, defined as systolic blood pressure values greater than or equal to 140mm / Hg and a diastolic blood pressure greater than or equal to 90mm / Hg.
• History of cardiovascular disease, blood disorders, kidney, pancreatic or thyroid disease.
• Women with suspicion or confirmation of pregnancy
• Women in breastfeeding period.
• History of smoking at any intensity within 12 months prior to the start of the study.
• History of drug abuse or alcoholism.
• Inability to attend or answer the evaluations made in each of the visits.
• Pacemaker bearing, or any other permanent bioelectronic element that can modify the electric bioimpedance reading or be affected by it.

Sponsors & Collaborators

• Coordinación de Investigación en Salud, Mexico: lead

Study Sites (1)

Biomedical Unit Research 02, Specialties Hospital, Medical Unit of High Specialty, West National Medical Center, Mexican Social Security Institute.

Guadalajara, Jalisco, 44380, Mexico

Location

Related Publications (56)

• Sonne DP, Hemmingsen B. Comment on American Diabetes Association. Standards of Medical Care in Diabetes-2017. Diabetes Care 2017;40(Suppl. 1):S1-S135. Diabetes Care. 2017 Jul;40(7):e92-e93. doi: 10.2337/dc17-0299. No abstract available.

  PMID: 28637892 BACKGROUND

• Organización Mundial de la Salud. Informe mundial sobre la diabetes. Ginebra, 2016

  BACKGROUND

• Instituto Nacional de Salud Pública. Encuesta Nacional de Salud y Nutrición de Medio Camino 2016 Informe Final de Resultados. 2016.

  BACKGROUND

• Asociación Latinoamericana de Diabetes. Consenso de Prediabetes. Documento de Posición de la Asociación Latinoamericana de Diabetes (ALAD) 2016.

  BACKGROUND

• National Institute for Health and Care Excellence. Preventing type 2 diabetes: risk identification and interventions for individuals at high risk. Public health guideline [PH38] 2012.

  BACKGROUND

• Bautista Rodríguez LM, Zambrano Plata GE. La calidad de vida percibida en pacientes diabéticos tipo 2. Investigación en Enfermería: Imagen y Desarrollo. 2015;17(1):131-148.

  BACKGROUND

• Guía de Práctica Clínica. Diagnóstico y tratamiento de la retinopatía diabética, 2015. Guía de Referencia Rápida. Catálogo Maestro de Guías de Práctica Clínica: Actualización 2015, IMSS-171-09

  BACKGROUND

• Chiarelli F, Trotta D, Verrotti A, Mohn A. Kidney involvement and disease in patients with diabetes. Panminerva Med. 2003 Mar;45(1):23-41.

  PMID: 12682618 BACKGROUND

• Najafian B, Alpers CE, Fogo AB. Pathology of human diabetic nephropathy. Contrib Nephrol. 2011;170:36-47. doi: 10.1159/000324942. Epub 2011 Jun 9.

  PMID: 21659756 BACKGROUND

• Pedraza L. Diabetic neuropathies: classification and diagnosis. Rev. Med. Clin. Condes 2009; 20(5) 681-686.

  BACKGROUND

• Julio RA. Galleguillos I. Diabetes and peripheral vascular disease. Rev. Med. Clin. Condes 2009; 20(5) 687-697.

  BACKGROUND

• Ampudia-Blasco FJ, Navarro J. [Cardiovascular disease in diabetes mellitus]. Med Clin (Barc). 2002 Mar 9;118(8):306-11. doi: 10.1016/s0025-7753(02)72367-1. No abstract available. Spanish.

  PMID: 11888500 BACKGROUND

• Arauza A, Ruíz-Franco A. Enfermedad vascular cerebral. Rev Fac Med UNAM 2012; 55 (3): 11-21.

  BACKGROUND

• Ruiz-Sandoval JL, Leon-Jimenez C, Chiquete-Anaya E, Sosa-Hernandez JL, Espinosa-Casillas CA, Cantu C, Villarreal J, Barinagarrementeria F, Ruiz-Sandoval JL, Arauz A, Leyva A, Murillo L, Alegria MA, Merino J, Romano J, Gonzalez-Vargas O; Asociacion Mexicana de Enfermedad Vascular Cerebral. [Lifestye and primary and secondary prevention for cerebrovascular disease]. Rev Invest Clin. 2010 Mar-Apr;62(2):181-91. No abstract available. Spanish.

  PMID: 20597398 BACKGROUND

• Cervantes-Villagrana RD, Presno-Bernal JM. Fisiopatología de la diabetes y los mecanismos de muerte de las células β pancreáticas. Rev Endocrinol Nutr 2013; 21(3): 98-106.

  BACKGROUND

• DeFronzo RA, Abdul-Ghani M. Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care. 2011 May;34 Suppl 2(Suppl 2):S202-9. doi: 10.2337/dc11-s221.

  PMID: 21525456 BACKGROUND

• D'Adamo E, Caprio S. Type 2 diabetes in youth: epidemiology and pathophysiology. Diabetes Care. 2011 May;34 Suppl 2(Suppl 2):S161-5. doi: 10.2337/dc11-s212. No abstract available.

  PMID: 21525449 BACKGROUND

• Gunawardane K, Krarup Hansen T, Sandahl Christiansen J, Lunde Jorgensen JO Normal physiology of growth hormone in adults. 2015; South Dartmouth, MA: Endotext.

  BACKGROUND

• Baumann G. Growth hormone binding protein. The soluble growth hormone receptor. Minerva Endocrinol. 2002 Dec;27(4):265-76.

  PMID: 12511849 BACKGROUND

• Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009 Apr;30(2):152-77. doi: 10.1210/er.2008-0027. Epub 2009 Feb 24.

  PMID: 19240267 BACKGROUND

• Krsek M. [Growth hormone, axis GH-IGF1 and glucose metabolism]. Vnitr Lek. 2016 Fall;62(11 Suppl 4):S62-66. Czech.

  PMID: 27921427 BACKGROUND

• Goodman y Gilman. Las bases farmacológicas de la terapéutica. 12va. ed. México: McGraw-Hill Interamericana; 2012.

  BACKGROUND

• Rajpathak SN, Gunter MJ, Wylie-Rosett J, Ho GY, Kaplan RC, Muzumdar R, Rohan TE, Strickler HD. The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. Diabetes Metab Res Rev. 2009 Jan;25(1):3-12. doi: 10.1002/dmrr.919.

  PMID: 19145587 BACKGROUND

• Chang HR, Kim HJ, Xu X, Ferrante AW Jr. Macrophage and adipocyte IGF1 maintain adipose tissue homeostasis during metabolic stresses. Obesity (Silver Spring). 2016 Jan;24(1):172-83. doi: 10.1002/oby.21354. Epub 2015 Dec 10.

  PMID: 26663512 BACKGROUND

• Binoux M. The IGF system in metabolism regulation. Diabete Metab. 1995 Dec;21(5):330-7.

  PMID: 8586149 BACKGROUND

• Aguirre GA, De Ita JR, de la Garza RG, Castilla-Cortazar I. Insulin-like growth factor-1 deficiency and metabolic syndrome. J Transl Med. 2016 Jan 6;14:3. doi: 10.1186/s12967-015-0762-z.

  PMID: 26733412 BACKGROUND

• Clemmons DR. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol. 1998 May 25;140(1-2):19-24. doi: 10.1016/s0303-7207(98)00024-0.

  PMID: 9722163 BACKGROUND

• Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Annu Rev Biochem. 2000;69:373-98. doi: 10.1146/annurev.biochem.69.1.373.

  PMID: 10966463 BACKGROUND

• O'Neill BT, Lauritzen HP, Hirshman MF, Smyth G, Goodyear LJ, Kahn CR. Differential Role of Insulin/IGF-1 Receptor Signaling in Muscle Growth and Glucose Homeostasis. Cell Rep. 2015 May 26;11(8):1220-35. doi: 10.1016/j.celrep.2015.04.037. Epub 2015 May 14.

  PMID: 25981038 BACKGROUND

• Von Bernhardi M R. Mecanismos de muerte celular en las enfermedades neurodegenerativas: ¿apoptosis o necrosis? Rev Chil Neuro-Psiquiat 2004;42(4):281-92.

  BACKGROUND

• Navarro M, Baserga R. Limited redundancy of survival signals from the type 1 insulin-like growth factor receptor. Endocrinology. 2001 Mar;142(3):1073-81. doi: 10.1210/endo.142.3.7991.

  PMID: 11181521 BACKGROUND

• Miyake H, Kanazawa I, Sugimoto T. Decreased serum insulin-like growth factor-I level is associated with the increased mortality in type 2 diabetes mellitus. Endocr J. 2016 Sep 30;63(9):811-818. doi: 10.1507/endocrj.EJ16-0076. Epub 2016 Jun 25.

  PMID: 27349183 BACKGROUND

• Sánchez-Migallón P. Control metabólico en pacientes diabéticos tipo 2: grado de control y nivel de conocimientos (Estudio Azuer) Rev Clin Med Fam 2011; 4(1): 32-4132.

  BACKGROUND

• Norma Oficial Mexicana NOM-015-SSA2-1994, Para la prevención, tratamiento y control de la diabetes.

  BACKGROUND

• Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015 Jan;38(1):140-9. doi: 10.2337/dc14-2441. No abstract available.

  PMID: 25538310 BACKGROUND

• Panickar K, Cao H, Qin B, Anderson RA. Molecular Targets and Health Benefits of Cinnamon. In: Aggarwal BB, Kunnumakkara AB, editors. Molecular Targets and Therapeutic Uses of Spices. Modern Uses for Ancient Medicine. USA:World Scientific; 2009. p. 87-115.

  BACKGROUND

• Ziegenfuss TN, Hofheins JE, Mendel RW, Landis J, Anderson RA. Effects of a water-soluble cinnamon extract on body composition and features of the metabolic syndrome in pre-diabetic men and women. J Int Soc Sports Nutr. 2006 Dec 28;3(2):45-53. doi: 10.1186/1550-2783-3-2-45.

  PMID: 18500972 BACKGROUND

• Khan A, Safdar M, Ali Khan MM, Khattak KN, Anderson RA. Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care. 2003 Dec;26(12):3215-8. doi: 10.2337/diacare.26.12.3215.

  PMID: 14633804 BACKGROUND

• Blevins SM, Leyva MJ, Brown J, Wright J, Scofield RH, Aston CE. Effect of cinnamon on glucose and lipid levels in non insulin-dependent type 2 diabetes. Diabetes Care. 2007 Sep;30(9):2236-7. doi: 10.2337/dc07-0098. Epub 2007 Jun 11. No abstract available.

  PMID: 17563345 BACKGROUND

• Lakshmi BS, Sujatha S, Anand S, Sangeetha KN, Narayanan RB, Katiyar C, Kanaujia A, Duggar R, Singh Y, Srinivas K, Bansal V, Sarin S, Tandon R, Sharma S, Singh S. Cinnamic acid, from the bark of Cinnamomum cassia, regulates glucose transport via activation of GLUT4 on L6 myotubes in a phosphatidylinositol 3-kinase-independent manner. J Diabetes. 2009 Jun;1(2):99-106. doi: 10.1111/j.1753-0407.2009.00022.x.

  PMID: 20929506 BACKGROUND

• Ravindran PN, Nirmal Babu K, Shylaja M. Cinnamon and Cassia. The genus Cinnamomum. 2004 CRC Press LLC. Boca Raton Florida, USA.

  BACKGROUND

• Meena Vangalapati, Sree Satya N, Surya Prakash DV, Sumanjali Avanigadda. A Review on Pharmacological Activities and Clinical effects of Cinnamon Species. RJPBCS 2012; 3(1) 653-663.

  BACKGROUND

• Nandam Sree Satya, Surya Prakash D.V., Vangalapati Meena. Purification of Cinnamaldehyde from Cinnamon Species by Column Chromatography. Res J Biological Sci 2012: 1(7): 49-51.

  BACKGROUND

• Jiaju Zhou, Guirong Xie, Xinjian Yan. Encyclopedia of Traditional Chinese Medicines - Molecular Structures, Pharmacological Activities, Natural Sources and Applications: Vol. 4: Isolated Compounds N-S. Editorial Springer-Verlang Berlin Heidelberg 2011. p. 535.

  BACKGROUND

• Warrier PK, Nambiar VPK, Ramankutty C. Indian Medicinal Plants: A Compendium of 500 Species. Orient Longman, 1994.

  BACKGROUND

• Cheng DM, Kuhn P, Poulev A, Rojo LE, Lila MA, Raskin I. In vivo and in vitro antidiabetic effects of aqueous cinnamon extract and cinnamon polyphenol-enhanced food matrix. Food Chem. 2012 Dec 15;135(4):2994-3002. doi: 10.1016/j.foodchem.2012.06.117. Epub 2012 Jul 14.

  PMID: 22980902 BACKGROUND

• Fugh-Berman A. The 5-minute Herb and Dietary Supplement Consult. Lyppincott Williams & Wilkins 2003. p.86-87.

  BACKGROUND

• Kirkham S, Akilen R, Sharma S, Tsiami A. The potential of cinnamon to reduce blood glucose levels in patients with type 2 diabetes and insulin resistance. Diabetes Obes Metab. 2009 Dec;11(12):1100-13. doi: 10.1111/j.1463-1326.2009.01094.x.

  PMID: 19930003 BACKGROUND

• Kim W, Khil LY, Clark R, Bok SH, Kim EE, Lee S, Jun HS, Yoon JW. Naphthalenemethyl ester derivative of dihydroxyhydrocinnamic acid, a component of cinnamon, increases glucose disposal by enhancing translocation of glucose transporter 4. Diabetologia. 2006 Oct;49(10):2437-48. doi: 10.1007/s00125-006-0373-6. Epub 2006 Aug 9.

  PMID: 16896937 BACKGROUND

• Imparl-Radosevich J, Deas S, Polansky MM, Baedke DA, Ingebritsen TS, Anderson RA, Graves DJ. Regulation of PTP-1 and insulin receptor kinase by fractions from cinnamon: implications for cinnamon regulation of insulin signalling. Horm Res. 1998 Sep;50(3):177-82. doi: 10.1159/000023270.

  PMID: 9762007 BACKGROUND

• Clemmons DR. Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol Metab Clin North Am. 2012 Jun;41(2):425-43, vii-viii. doi: 10.1016/j.ecl.2012.04.017.

  PMID: 22682639 BACKGROUND

• Jeyaseelan L, Rao PS. Methods of determining sample sizes in clinical trials. Indian Pediatr. 1989 Feb;26(2):115-21.

  PMID: 2753525 BACKGROUND

• Brick DJ, Gerweck AV, Meenaghan E, Lawson EA, Misra M, Fazeli P, Johnson W, Klibanski A, Miller KK. Determinants of IGF1 and GH across the weight spectrum: from anorexia nervosa to obesity. Eur J Endocrinol. 2010 Aug;163(2):185-91. doi: 10.1530/EJE-10-0365. Epub 2010 May 25.

  PMID: 20501597 BACKGROUND

• Guerrero-Romero F, Simental-Mendia LE, Gonzalez-Ortiz M, Martinez-Abundis E, Ramos-Zavala MG, Hernandez-Gonzalez SO, Jacques-Camarena O, Rodriguez-Moran M. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010 Jul;95(7):3347-51. doi: 10.1210/jc.2010-0288. Epub 2010 May 19.

  PMID: 20484475 BACKGROUND

• Compendio de Leyes y Reglamentos. Agenda de Salud 2002. Tercera edición. México: Ediciones fiscals ISEF, 2002

  BACKGROUND

• Surós A, Surós J. Semiología médica y técnica exploratoria. Octava edición. Barcelona: MASSON, 2001

  BACKGROUND

Related Links

• Pubchem; 2017.Accessed at https://pubchem.ncbi.nlm.nih.gov on 15 June 2017.

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Study Officials

• Sandra O Hernández González, Doctorado

  Instituto Mexicano del Seguro Social, Unidad de Investigación Biomédica 02

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Masking Details: Random assignment of groups and blinding: All participants will be submitted to the selection of a sealed envelope which will have a numerical code previously defined by a third party for each intervention group. The total number of envelopes required to complete the minimum number of participants (28) will be divided according to sex in two boxes, there will be 14 envelopes for men and 14 envelopes for women, with numerical codes that identify the bottle of intervention treatment that should receive the participant during the intervention period. They will be divided into 7 blinded codes for cinnamomum cassia group and 7 for placebo to complete the size of each subsample. Chance guarantees blinding, neither the participant nor the researcher will know the type of treatment. The database for the blinded statistical analysis will be completed. The blind man will be removed once the statistical analysis has been completed.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Medical Research Associate C, Unit in Clinical Epidemiology, Specialities Hospital, Medical Unit of High Specialty; West National Medical Center, Mexican Institute of Social Security.

Model Details: Controlled clinical trial, of two parallel groups, double blind, with random assignment and control group. Process: Visit 1 / Day -7: Period of scrutiny, study information, consent signature, clinical history, anthropometry, baseline laboratory tests. Visit 2 / Day 0: Start the intervention period, simple random assignment for study groups, delivery of medication, general recommendations of diet and exercise. Visit 3 / Day 30 - Visit 4 / Day 60: Adherence to treatment, taking laboratory tests, evaluation of adverse events, general recommendations of diet and exercise, general recommendations of diet and exercise will be evaluated. Final Visit / Day 90 ± 7: Anthropometric measurements will be taken, laboratory tests will be taken, treatment adherence and adverse events will be evaluated, end of the intervention period.

Study Record Dates

• First Submitted: March 23, 2018
• First Posted: August 1, 2018
• Study Start: August 1, 2019
• Primary Completion: November 24, 2020
• Study Completion: August 18, 2021
• Last Updated: July 22, 2022

Record last verified: 2022-07

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP
• Time Frame: Starting 6 months after publication.
• Access Criteria: The data can be shared through a request addressed to the principal investigator Dr. Sandra Ofelia Hernández González, basing the reason for what they are requested.

Locations

ME (1)